Verastem (NASDAQ:VSTM) Shares Gap Up – Time to Buy?

Shares of Verastem, Inc. (NASDAQ:VSTM) gapped up before the market opened on Wednesday. The stock had previously closed at $7.45, but opened at $8.00. Verastem shares last traded at $8.7640, with a volume of 10,572,543 shares traded.

Key Stories Impacting Verastem

Here are the key news stories impacting Verastem this week:

• Positive Sentiment: Promising VS-7375 data: Verastem reported robust anti-tumor activity in patients with KRAS G12D-mutated pancreatic, lung and colorectal cancers. The company highlighted a 50% confirmed objective response rate in second-line pancreatic ductal adenocarcinoma and two complete responses in second-line or later disease, supporting the drug’s potential ahead of late-stage testing. VS-7375 clinical data
• Positive Sentiment: Substantial funding secured: Verastem priced a $250 million underwritten offering, with proceeds intended to support VS-7375 development and planned late-stage studies. The financing strengthens the company’s balance sheet and extends its ability to advance the program. $250 million offering
• Neutral Sentiment: Planned leadership change: Michael P. Bailey will become president and CEO on January 1, 2027, replacing retiring CEO Daniel Paterson. The transition is planned rather than prompted by an immediate setback, but investors may evaluate Bailey’s ability to execute the company’s late-stage development strategy. CEO transition announcement
• Negative Sentiment: Shareholder dilution: Issuing more than 30.9 million common shares, along with pre-funded warrants, dilutes existing holders. The $8 offering price may also create a near-term reference point for the stock, partially offsetting the positive impact of the clinical update.

Analyst Upgrades and Downgrades

Several research firms have commented on VSTM. Wolfe Research initiated coverage on shares of Verastem in a report on Thursday, September 17th. They issued an “outperform” rating on the stock. Guggenheim set a $12.00 target price on shares of Verastem and gave the stock a “buy” rating in a research note on Friday, August 7th. Wall Street Zen raised shares of Verastem from a “sell” rating to a “hold” rating in a report on Sunday, September 27th. Weiss Ratings raised shares of Verastem from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, September 4th. Finally, BTIG Research reissued a “buy” rating and issued a $18.00 price target on shares of Verastem in a report on Monday, October 5th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $13.83.

Verastem Stock Up 17.8%

The firm has a 50-day simple moving average of $7.50 and a two-hundred day simple moving average of $5.89. The stock has a market cap of $794.66 million, a P/E ratio of -3.34 and a beta of 0.39. The company has a current ratio of 2.25, a quick ratio of 2.22 and a debt-to-equity ratio of 1.48.

Verastem (NASDAQ:VSTM) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.08. Verastem had a negative net margin of 231.59% and a negative return on equity of 467.49%. The business had revenue of $40.08 million during the quarter, compared to analysts’ expectations of $22.88 million. Equities research analysts expect that Verastem, Inc. will post -1.55 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Dan Paterson sold 44,121 shares of the business’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $8.00, for a total value of $352,968.00. Following the completion of the transaction, the chief executive officer owned 652,712 shares of the company’s stock, valued at $5,221,696. The trade was a 6.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 48,044 shares of company stock worth $381,484. Corporate insiders own 1.94% of the company’s stock.

Institutional Investors Weigh In On Verastem

A number of large investors have recently modified their holdings of VSTM. Seven Fleet Capital Management LP acquired a new position in Verastem during the 4th quarter worth approximately $117,000. Hsbc Holdings PLC bought a new stake in shares of Verastem during the first quarter worth $210,000. ADAR1 Capital Management LLC bought a new position in shares of Verastem in the 1st quarter valued at $377,000. Quantinno Capital Management LP bought a new stake in Verastem during the 1st quarter worth $394,000. Finally, Knott David M Jr bought a new position in Verastem in the first quarter valued at about $551,000. Institutional investors and hedge funds own 88.37% of the company’s stock.

Verastem Company Profile

Verastem Oncology (NASDAQ:VSTM) is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancers driven by abnormalities in the RAS/MAPK signaling pathway. The company’s research is aimed at addressing cancers with limited treatment options, including ovarian cancer and other solid tumors.

Verastem’s lead product, avutometinib, is a treatment targeting the RAF/MEK signaling pathway and is marketed in the United States under the brand name Avmapki for certain patients with recurrent low-grade serous ovarian cancer.